Post-discharge wearable mobility data predict readmission and mortality in

A prospective study in Supportive Care in Cancer suggests that post-discharge mobility tracked through consumer wearables can forecast which patients with stage IV solid tumors are most likely to be readmitted or die within 90 days. Conducted at two tertiary oncology centers in Ankara, Turkey, and registered on ClinicalTrials.gov (NCT06687330), the trial enrolled 200 adults discharged after an unplanned hospitalization. Participants wore wrist activity trackers, and researchers analyzed median daily step counts during a prespecified 14-day window after discharge. The primary endpoint was unplanned readmission within 90 days, with all-cause mortality as a secondary endpoint. Overall, 43.0% were readmitted and 28.0% died within 90 days. Using receiver operating characteristic analysis, 3,013 steps per day emerged as the cutoff: readmission was 73.0% at or below it versus 13.0% above; mortality was 47.0% versus 9.0%.